Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
SIGA Technologies Inc(SIGA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SIGA
09/28/2026: SIGA (1-star) is currently NOT-A-BUY. Pass it for now.
SIGA Technologies is a specialized biotechnology company known for TPOXX, the only FDA-approved antiviral treatment for smallpox. Its business model is defined by long-term procurement contracts with the U.S. government, providing strong operating margins but creating high revenue concentration risk. While the company holds a leading position in the niche biodefense market, its growth is cyclical and tied to international pandemic preparedness and contract renewals. Potential investors should weigh the benefits of this unique government-backed revenue against risks like product dependency and political uncertainty. SIGA may suit investors looking for exposure to biodefense themes, though its performance remains subject to significant volatility and the unpredictable nature of global health crises.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Growth is lumpy and highly dependent on government procurement cycles rather than steady commercial expansion. |
| Momentum investor | Strong fit while signal remains positive | The stock often experiences sharp upward movements during periods of heightened global concern regarding infectious disease outbreaks. |
| Value investor | Mixed fit | While valuation may look attractive during lulls in contracting, the underlying business quality is highly specialized and niche. |
| Dividend investor | Weak fit | The company does not provide a reliable or consistent dividend yield, preferring discretionary capital returns. |
| Low-risk investor | Weak fit | High volatility and sensitivity to government policy make this a risky asset for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to news regarding government contracts and global health emergencies. |
| Valuation risk | Medium | Valuation is often disconnected from traditional earnings multiples due to the cyclical nature of contract revenues. |
| Competition risk (Biodefense/Vaccine sector) | Medium | Potential competition from new vaccines or alternative therapies could impact future government procurement decisions. |
| Business quality | Medium | The business model relies on a single dominant product and a very small pool of government customers. |
| Dividend income | Low / none | Investors should not rely on SIGA for consistent income generation. |
| Execution risk | Medium | Timely delivery and adherence to rigorous government contract specifications are critical to maintaining revenue. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -12.3% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 247.88M USD | Price to earnings Ratio - | 1Y Target Price 17.53 |
Price to earnings Ratio - | 1Y Target Price 17.53 | ||
Volume (30-day avg) 721.6K shares | Beta 0.89 | 52 Weeks Range 2.83 - 8.22 | Updated Date 09/27/2026 |
52 Weeks Range 2.83 - 8.22 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.04 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Sales (TPOXX) | Direct sales of TPOXX to the U.S. government and international health agencies. | The company makes money when governments buy its drug for their emergency stockpiles. |
| Geography (U.S. vs. International) | Primary revenue stems from the U.S. government, with growing efforts to expand into international markets. | Most revenue is U.S.-focused, making the company dependent on American federal spending. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 2.94 | Enterprise Value 111.34M | Price to Sales(TTM) 4.62 |
Enterprise Value 111.34M | Price to Sales(TTM) 4.62 | ||
Enterprise Value to Revenue 2.07 | Enterprise Value to EBITDA 3.71 | Shares Outstanding 71.85M | Shares Floating 41.13M |
Shares Outstanding 71.85M | Shares Floating 41.13M | ||
Percent Insiders 42.73 | Percent Institutions 50.44 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About SIGA Technologies Inc
Exchange NASDAQ | Headquarters New York, NY, United States | ||
IPO Launch date 1997-09-09 | CEO & Director Dr. Diem Nguyen M.B.A., Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 49 | Website https://www.siga.com |
Full time employees 49 | Website https://www.siga.com | ||
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.